Trial Profile
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 24 Aug 2015
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 Mar 2013 Planned End Date changed from 1 Dec 2012 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 04 Mar 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.